Assembly Biosciences Inc (ASMB)
Assembly Biosciences, Inc. is a NASDAQ-listed biotechnology company focused on developing therapeutic candidates for viral diseases. Its pipeline includes long-acting helicase-primase inhibitor programs ABI-5336 and ABI-1179, both in Phase 1a/1b studies for recurrent genital herpes, as well as ABI-4334, a capsid assembly modulator being studied in Phase 1b for hepatitis B virus. The company is also advancing ABI-6250, an oral hepatitis delta virus entry inhibitor in Phase 1a testing, and ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor aimed at transplant-related herpesviruses. Assembly Biosciences has an option, license, and collaboration agreement with Gilead Sciences for virology research and development. Founded in 2005 and headquartered in South San Francisco, California, the company was formerly known as Ventrus Biosciences, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ASMB
|
$26.01
|
-1.2% Downside
|
Fair
|
$50
|
89.9% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-81.5x
|
2.6x
|
7.3x
|
496.6 M
|
295.9 M
|
0.5%
|
55.4%
|
4.2
|
—
|
624.1%
|
